Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 483 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... November 14, 2024 FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma... April 11, 2025 BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... April 4, 2022 Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal... May 20, 2022 Load more HOT NEWS Sing Anyway VA Study Finds No Disparities in Prostate Cancer Deaths with Equal... 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain... Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and...
